Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*

Douglas H. Thamm1, Debra A. Kamstock1, Claire R. Sharp2, Scott I. Johnson3, Elisa Mazzaferrro4, Lee V. Herold5, Susan M. Barnes6, Kevin Winkler7 and Kimberly A. Seling8

1Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA
2Tufts University, North Grafton, MA, USA
3Emergency Animal Hospital of NW Austin, Austin, TX, USA
4Wheat Ridge Veterinary Specialists, Wheat Ridge, CO, USA
5Dove Lewis Emergency Animal Hospital, Portland, OR, USA
6Animal Emergency Critical Care, The LifeCentre, Leesburg, VA, USA
7Georgia Veterinary Specialists, Atlanta, GA, USA
8University of Missouri, Columbia, MO, USA

Abstract
Thymidine kinase 1 (TK1) is a soluble biomarker associated with DNA synthesis. This prospective study evaluated serum TK1 activity in dogs presenting with hemoabdomen and a splenic mass. An ELISA using azidothymidine as a substrate was used to evaluate TK1 activity. Sixty-two dogs with hemoabdomen and 15 normal controls were studied. Serum TK1 activity was significantly higher in dogs with hemangiosarcoma (HSA) than in normal dogs (mean ± SEM = 17.0 ± 5.0 and 2.01 ± 0.6, respectively), but not dogs with benign disease (mean ± SEM = 10.0 ± 3.3). Using a cut-off of 6.55 U/L, TK1 activity demonstrated a sensitivity of 0.52, specificity of 0.93, positive predictive value of 0.94 and negative predictive value of 0.48 for distinguishing HSA versus normal. When interval thresholds of <1.55 and >7.95 U/L were used together, diagnostic utility was increased. Serum TK1 evaluation may help to discriminate between benign disease and HSA in dogs with hemoabdomen and a splenic mass.

Keywords
angiosarcoma, biomarker, cancer, dog, hemoabdomen